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Kaposi’s sarcoma-associated herpesvirus (also called human herpesvirus 8 [HHV-8]) replication and tran-
scription activator (RTA) is apparently necessary and sufficient for the switch from viral latency to lytic
replication. RTA may regulate open reading frame (ORF) K14 (viral OX-2 homologue) and ORF74 (viral
G-protein-coupled receptor homologue) genes through an interferon-stimulated response element (ISRE)-like
sequence (K14 ISRE) in the promoter region. RTA strongly activated a K14 ISRE-containing K14-ORF74
promoter reporter construct and a heterologous promoter reporter construct containing K14 ISRE. RTA could
bind to K14 ISRE and other ISREs, activate promoter reporter constructs from interferon-simulated genes
(ISGs), and selectively induce three endogenous ISGs in primary endothelial cells: ISG-54, myxovirus resis-
tance protein 1 (MxA), and stimulated trans-acting factor of 50 kDa. In addition, a region in the RTA
DNA-binding domain has been identified with certain sequence similarity to the DNA-binding domains of the
interferon regulatory factor (IRF) family. Mutation in one conserved amino acid within this region reduced the
ability of RTA to bind to ISRE as well as other RTA response elements. Furthermore, the mutant failed to
activate RTA-responsive promoters and to induce viral lytic gene expression. The mutation at the same
conserved amino acid residue in IRF-7 drastically reduced its ability to bind to DNA and to activate the beta
interferon promoter. The sequence and functional similarities between RTA and IRFs suggest that the HHV-8
RTA may usurp the cellular IRF pathway.
Human herpesvirus 8 (HHV-8), also known as Kaposi’s sar-
coma (KS)-associated herpesvirus, is a gammaherpesvirus. It
was first discovered in KS specimens and is believed to be the
etiological agent of KS (7, 8, 39). In addition, HHV-8 is im-
plicated in the pathogenesis of other human cancers, including
AIDS-associated body cavity-based lymphoma (BCBL), also
called primary effusion lymphoma (PEL), and a lymphoprolif-
erative disorder known as multicentric Castleman’s disease
(16, 39, 68).
HHV-8 goes through both latency and lytic replication cy-
cles. The switch from latency to lytic replication in HHV-8
resembles that of other gammaherpesviruses, such as Epstein-
Barr virus (EBV). The expression of the HHV-8 replication
and transcription activator (RTA) is apparently necessary and
sufficient for the switch from latency to lytic replication (16,
68). RTA is an immediate-early gene (51, 61, 77) and a se-
quence-specific DNA-binding protein. The N-terminal amino
acids 1 to 272 are sufficient for DNA binding in vitro (35). A
number of RTA-responsive elements (RREs) were identified
in the transcriptional regulatory regions of different subse-
quently expressed viral genes (21, 36, 49, 52, 60, 61, 77) and
were found to consist of long and poorly defined sequences
that could be tandem arrays of phased A/T trinucleotide motifs
(Table 1) (14, 17, 30, 47, 49, 57, 59).
RTA interacts with other factors to modulate its transcrip-
tion potential (22, 24, 31, 65). A cellular zinc finger protein,
K-RBP (KS-associated herpesvirus RTA-binding protein), in-
teracts with RTA and functions as a cellular cofactor to mod-
ulate viral gene expression (65). RTA also interacts physically
with recombination signal sequence-binding protein J kappa
(RBP-J) (also known as CBF-1 and CSL) in the transactiva-
tion of viral promoters (28). The RTA–RBP-J complex ap-
pears to be essential for the RTA-mediated switch from la-
tency to lytic replication (29). Beyond functioning in initiating
viral lytic replication, RTA is involved in the induction of
cellular interleukin-6 (IL-6) (13). RTA also blocks p53-medi-
ated apoptosis by competing for binding to CBP (23).
HHV-8 ORF K14 (viral OX-2 homologue [vOX-2]) and
ORF74 (viral G-protein-coupled receptor homologue [vGPCR])
genes are expressed from a bicistronic mRNA in the lytic repli-
cation cycle (26). K14 (vOX2) provides an activating signal for
the production of inflammatory cytokines that potentially pro-
mote cytokine-mediated angiogenic proliferation of HHV-8-
infected cells (11). ORF74 (vGPCR) can induce immortaliza-
tion and recapitulate certain aspects of KS angiogenesis and
oncogenesis in human primary endothelial cells (4, 38), and it
is thus thought to be one of the pathogenic determinants in the
development of KS.
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Interferon (IFN) regulatory factors (IRFs) are a small family
of transcription factors with multiple functions, including virus-
induced IFN production, modulation of apoptosis, latency,
transformation, and immune response pathways (43, 55, 62,
75). The hallmark of the family is a conserved N-terminal
DNA-binding domain which mediates binding to the core re-
gion of IFN-stimulated response elements (ISREs) and
thereby regulates IFN-responsive promoters. The C-terminal
portion of the IRF family is variable and defines its biological
functions (43, 55, 62, 75).
HHV-8 and IRFs have an intriguing relationship. The
HHV-8 genome contains four viral IRF homologues (vIRFs)
(45). Although none of them have been shown to bind to
ISRE, both vIRF-1 and -3 are capable of blocking the produc-
tion of IFN upon virus infection (19, 32, 34). In addition, the
ORF45 protein interacts with IRF-7 and blocks IRF-7-medi-
ated IFN production (78). Other gammaherpesviruses also
have been shown to interact with members of the IRF family.
Notably, EBV induces the expression of IRF-7 and activates
IRF-7 protein by phosphorylation and nuclear translocation
(71–75), and the rhesus rhadinovirus genome has been shown
to contain eight IRF homologues (1).
In this report, we show that RTA has a region with similarity
to DNA-binding domains of IRF family proteins. RTA binds
to ISRE specifically and regulates HHV-8 K14-ORF74 genes
through an ISRE-like sequence in the promoter region. RTA
also selectively induces cellular IFN-stimulated genes (ISGs).
Since ISGs are induced during HHV-8 lytic replication, our
findings suggest a strong interplay between HHV-8 RTA and
the IFN signaling pathway, which may play an important role
in HHV-8 biology.
MATERIALS AND METHODS
Plasmids and antibodies. Expression plasmids of RTA (pCMV-Tag50) and
mutants (pCMV-RTA-AD1, AD2, AD3, and AD4) were described elsewhere
(64). Another RTA expression plasmid, pCMV50, was a gift from Byrd Quin-
livan (54). Human ISG54-luc and IFI6-16-luc were gifts from Ahmet Civas (20).
The IFN--promoter reporter was a gift from Rongtuan Lin and John Hiscott
(33). The IRF-7 expression plasmid has been described previously (74). The
mutants RTA-P102T, RTA-F120D, RTA-K158E, RTA-A158P, and IRF7-K92E
were obtained with the use of a PCR mutagenesis kit (Invitrogen). The complete
coding sequence of Tag-RTA or Tag-RTA K152E was inserted into pET28b
(Novagen) at the EcoRI and XhoI sites to generate pET28b-RTA or pET28b-
RTA K152E, respectively, for bacterial expression. The recombinant adenovirus
for RTA (AdRTA) and for green fluorescence protein (AdGFP) were gifts from
Byrd Quinlivan (54). The -galactosidase expression plasmid pCMV was pur-
chased from Clontech (BD Biosciences, Palo Alto, CA). The K14-ORF74 pro-
moter reporter constructs were generated by inserting the PCR products into the
pGL3-basic vector (Promega, Madison, WI). Two oligos, 5-GATCGTGAGAA
ACAGAAACGGCGATCGTGAGAAACAGAAACGGCGATCGTGAGAAA
CAGAAACGGC-3 and its complementary strand, with GATC at the 5 end,
were used for cloning 3xK14 ISRE into the pGL3-promoter vector (K14ISRE-
Luc). mK14 ISRE-Luc was made in the same way except for mutations at the
desired nucleotides, as shown below in Fig. 1A. All mutations were verified by
sequence analysis by the UNL Sequencing Facility. RTA antibodies were from
David Lukac (see Fig. 6 and 7 below) and Gary Hayward (see Fig. 3, 4, and 5,
below); K8 and K8.1 antibodies were obtained from Jae Jung; vIRF-1 antibody
was from Yuan Chang; vIL-6 antibody was from John Nicholas; ISG-15 was from
Ernest Bordin; and MxA antibody was from Mark A. McNiven. Tubulin and
Flag-antibodies were purchased from Sigma. IRF-1 antibody was from Santa
Cruz. IRF-7 antibody was described elsewhere (74). Sendai virus stock was
purchased from Spafas, Inc.
Western blot analysis, RNA extraction, and RPA. Standard Western blot
analysis was performed as described previously (70–72). Total RNA was isolated
from cells by using the RNeasy total RNA isolation kit (QIAGEN, Valencia,
CA). RNase protection assays (RPA) were performed with total RNA using the
RNase protection assay kit II (Ambion, Houston, TX). The glyceraldehyde-3-
phosphate dehydrogenase (GAPDH) probe was from U.S. Biochemicals, Inc.
The probe for stimulated trans-acting factor of 50 kDa (STAF-50) was made
from the PCR product amplified using the two primers from STAF-50: 5-GG
GGTACCGACGTCATGAAAAGGAGTG-3 and 5-GGATTTGAATTCTTA
AATGTG-3. The resultant PCR products were cloned into a pcDNA3.1 vector.
The probe for IRF-7 was described before (69, 71).
Expression and purification of HHV-8 RTA. Escherichia coli BL21(DE3) cells
harboring the pET28b-RTA or pET28b-RTA K152E plasmid were induced for
4 h with 0.5 mM isopropylthio--D-galactoside at 28°C. After the induction,
proteins were purified with Ni2-nitrilotriacetic acid (NTA) agarose (QIAGEN,
Valencia, CA) under the nondenaturing conditions suggested in the QIAexpres-
sionist manual. Fractions containing target proteins were dialyzed against phos-
phate-buffered saline buffer (pH 7.4), separated into aliquots, and stored at
70°C.
EMSA. The probes were obtained by first annealing complementary oligonu-
cleotides and then labeling them with [-32P]dATP (Amersham) using DNA
polymerase Klenow fragment (Fermentas). The K14 ISRE probe was obtained
by annealing two oligonucleotides, 5-ACAGGTACCGTGAGAAACAGAAAC
GGC-3 and its complementary strand, with ACAGGTACC at the 5 end. The
mK14ISRE probe was made exactly the same way as the K14 ISRE, with the
mutations in the proper places as shown below in Fig. 1A. The oligos, 5-GAT
CAGCCCGCGGGAATCGAAAGCC-3 and its complementary strand, with
GATC at the 5 end, were used for the vIL6 ISRE-1 probe. The consensus ISRE
probe from ISG-15 was synthesized according to the methods described in a
previous report (27). Tap-2 ISRE and mTap2 ISRE probes were described
earlier (72). The 5 overhangs of the probes were filled in by DNA polymerase
I Klenow fragment and purified with the QIAquick nucleotide removal kit
(QIAGEN). An electrophoretic mobility shift assay (EMSA) was performed
essentially as described previously (59). Basically, labeled probes were purified
with the QIAquick nucleotide removal kit (QIAGEN). The purified RTA pro-
tein was incubated with 20,000 to 50,000 cpm of labeled probe in a volume of 12.5
l containing 20 mM HEPES-KOH (pH 7.9), 1 mM MgCl2, 0.1 mM EGTA, 2 g
of poly(dI-dC), 4% Ficoll for 20 min at room temperature. When antibody was
used, 0.1 l of antibody was incubated with the reaction mixture for 15 min prior
to the addition of probe. Various amounts of Ni2-NTA agarose beads were
incubated with RTA proteins, the beads were collected by centrifuging, and the
supernatants were used for EMSA. Glutathione-Sepharose 4B beads (Amer-
sham) (GST beads) were used as a control for Ni2-NTA beads. The binding
mixtures were separated on a 4.5% polyacrylamide gel in 0.25 Tris-borate-
EDTA buffer.
Cell culture, transient transfection, and reporter assays. BCBL-1 and BC-3
are HHV-8-positive PEL cell lines (2). DG75 is an HHV-8-negative Burkitt’s
lymphoma cell line. These cells were maintained in RPMI 1640 plus 10% fetal
bovine serum. Electroporation was used for transfection of these B cells as
described previously (71, 72, 76). 293T cells were maintained in Dulbecco’s
modified Eagle’s medium plus 10% fetal bovine serum. Effectene (QIAGEN)
was used for the transfection of 293T cells. HUVEC are human primary umbil-
ical vascular endothelial cells (gift from Lingjun Zhao) and were maintained in
TABLE 1. Sequence comparison of RRE and ISREsa
Consensus RREb ...........................(A/T)3N7(A/T)3N7(A/T)3 or
(A/T)3N17(A/T)3
K14 ISRE .......................................GAGAAACAGAAACG
Tap2 ISRE......................................GCGAAAGCGAAAGC
vIL6 ISRE1 ....................................GGGAAT-CGAAAGC
ISG15 ISRE ...................................GGGAAAGGGAAACCGAAACT
ISG54 ISRE ...................................GGGAAAGTGAAACT
IFI6-16 ISRE1/2c ...........................GGGAAAATGAAACT
MxA ISRE2d ..................................CAGAAA-CGAAACC
MxA ISRE3....................................AAGAAA-TGAAACA
Consensus ISREe ...........................(A/G)NGAAANNGAAACT
a RTA-binding or potentially regulated ISREs are characterized in this report.
b From Liao et al. (30).
c IFI6-16 has two identical ISREs.
d MxA has three ISREs; the two responsive to IFN induction are shown.
e From Darnell (12).
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the EBM-2 plus medium (Cambrex). The luciferase assays were performed using
the assay kit from Promega according to the manufacturer’s recommendations.
Isolation of transfected cells and in vitro translation. Enrichment for CD4-
positive cells was performed with anti-CD4 antibody conjugated to magnetic
beads according to the manufacturer’s recommendations (Dynal, Inc.). The
isolated cells were lysed immediately and used for Western blot analysis. For in
vitro transcription and translation, the TNT-coupled transcription and transla-
tion kit (Promega) was used essentially as specified by the manufacturer.
Induction of viral lytic replication. BC-3 was transfected with various report-
ers. After overnight recovery, these cells were treated with 20 ng/ml 12-O-
tetradecanoylphorbol-13-acetate (TPA) for 24 h to induce lytic viral replication.
After induction, the cells were harvested for reporter assays. For BCBL-1 cells,
20 ng/ml of TPA for 48 h was used for induction of lytic replication.
RT-coupled PCR. Total RNA was isolated from samples by using an RNeasy
kit (QIAGEN). The RNA samples were treated with DNase I at 37°C for 30 min.
The primers used in this experiment were as follows: for the actin gene, Actin 1
(5-TTC TAC AAT GAG CTG CGT GT-3) and Actin 2 (5-GCC AGA CAG
CAC TGT GTT GG-3); for the ISG-54 gene, ISG545 (5-AGAAATCAAGG
GAGAAAG-3) and ISG5431 (5-TCATTCCCCATTCCAGC-3). These prim-
ers were mixed with 0.1 g of RNA, reverse transcription (RT) reactions were
done in 50°C for 30 min, and PCRs were followed with standard protocols, with
30 cycles for the actin gene while 35 cycles for ISG-54 were used for PCR
amplification.
RESULTS
RTA may regulate ORF-K14 and ORF74 genes through an
ISRE-like sequence. K14 and ORF74 are transcribed together
as a bicistronic mRNA in the lytic replication cycle (10, 26). By
sequence analysis, an ISRE-like element, hereafter named K14
ISRE, was identified in the promoter region of K14-ORF74
(Fig. 1A). The K14 ISRE is almost identical to the consensus
ISRE sequence (12). The possible role of K14 ISRE in the
regulation of K14-ORF74 expression in lytic replication was
examined by using two promoter reporter constructs, K14A-
Luc and K14B-Luc, with or without the K14 ISRE sequence
(Fig. 1A). Since TPA can induce HHV-8-positive PEL cells
into lytic replication (60, 61, 77), whether the K14-ORF74
promoter constructs are responsive to TPA induction in HHV-
8-positive cells was examined. In HHV-8-positive BC-3 cells,
induction by TPA was threefold higher in cells transfected with
ISRE-containing K14A-luc compared to those with ISRE-lack-
ing K14B-luc (Fig. 1B). However, in HHV-8-negative DG75
cells, there was very little induction for either promoter re-
porter construct (Fig. 1B). These data suggest that a viral
gene(s) in the lytic replication cycle may be responsible for
activation of the K14-ORF74 promoter via K14 ISRE. RTA is
among the earliest gene products expressed upon TPA treat-
ment and has been shown to activate the K14-ORF74 pro-
moter (10, 26, 77); therefore, the putative role of RTA on K14
ISRE was examined. As shown in Fig. 1C, the K14-ORF74
promoter reporter construct with the ISRE (K14A-luc) re-
sponded to RTA extremely well, while the construct lacking
the element (K14B-luc) was only weakly activated by RTA. To
further test if K14 ISRE could mediate RTA activation, K14
ISRE was multimerized and placed upstream of a simian virus
40 minimum promoter reporter construct (Fig. 1A), and the
resulting reporter construct (K14LSRE-luc) was transfected
into cells with RTA. RTA was found to activate the K14
ISRE-containing heterologous promoter reporter construct
but not the corresponding mK14ISRE-containing reporter
construct (Fig. 1D). In addition, RTA failed to activate the
pGL3-promoter vector (data not shown). Thus, these results
suggest that K14 ISRE may be an important element used by
RTA for the activation of the K14-ORF74 promoter. Other
putative RREs, which are not K14 ISRE, have been identified
or predicted in the K14-ORF74 promoter region (Fig. 1A) (26,
30). Obviously, without the K14 RRE identified by Jeong et al.
(26), the K14 promoter is still activated by RTA (Fig. 1B and
C). However, additional putative RRE identified by Liao et al.
(30) could be responsible for the activation of the ISRE-lack-
ing K14-ORF74 promoter reporter construct (K14B-luc).
The RTA activation domain is required for activation of K14
ISRE. RTA has been shown to activate K14-ORF74 promoter
reporter constructs (10, 26), but the domain(s) that is involved
in the activation is not known. Therefore, different deletion
mutants of RTA were tested in order to identify the domains
of RTA that are necessary for K14-ORF74 activation. The
RTA AD1 to -4 mutants have various deletions in the activa-
tion domain, as shown in Fig. 2A, and none of them were able
to activate the K14-ORF74 promoter to the same extent as the
wild-type RTA (Fig. 2B). Similarly, the activation domain was
also required for the activation of K14 ISRE (Fig. 2C). Since
the expression levels of all RNA mutants were similar (Fig.
2D), this suggested that the activation domain of RTA is re-
quired for K14 ISRE-mediated activation of the K14-ORF74
promoter.
RTA binds to ISRE directly. The involvement of ISRE in the
activation of K14-ORF74 and the results in Fig. 2 suggest that
RTA might bind to ISRE directly. Partially purified RTA pro-
tein, which has been used widely to study RTA binding (14, 35,
58, 59, 66), was used for EMSA with the K14 ISRE probe.
Poly-histidine-tagged full-length RTA was expressed in bacte-
ria and partially purified using Ni2-NTA agarose beads (see
Materials and Methods for details). It was noted that the
purified RTA had the expected properties, as it binds to other
known RREs (see Fig. 5, below, and data not shown). As
shown in Fig. 3A, specific binding of RTA to the K14 ISRE was
observed in the EMSA. The band was specific, because it
disappeared in the presence of cold competitors such as K14
ISRE itself, the consensus ISRE for the ISG15 promoter, or
the ISRE from the transporter associated with antigen pro-
cessing 2 promoter (Tap2 ISRE) (lanes 3 and 5 to 7). However,
the mutated K14 ISRE and Tap2 ISRE had little effect on the
RTA-DNA complex formation (lanes 4 and 8). When Ni2-
NTA beads were incubated with purified RTA, the intensity of
the major protein-DNA complex decreased; however, the GST
beads had no effect (lanes 9 to 12). When RTA antibody was
added to the reaction mixture, a decrease in the intensity of the
major specific band was observed; however, an irrelevant K15
antibody had no effect (lanes 13 and 14). There was also a
nonspecific band. The nonspecific band was due to the reac-
tivity of the RTA antibody to DNA probe itself, as the probe
plus antibody also generated the same complex (lane 15).
Thus, from specific competition by cold probes, the effect of
Ni2-NTA beads, as well as reactivity to RTA antibody, the
major band was identified as an RTA-ISRE complex. In addi-
tion to K14 ISRE, RTA also binds specifically to these well-
established ISREs, e.g., ISRE-1 from vIL-6 promoters (Fig.
3B). Almost identical patterns could be observed when ISRE
from ISG-15 was used as probe (data not shown). Both vIL6
ISRE1 and ISG-15 ISRE were shown to be responsive to IFN
(9, 27). These results strongly suggest that RTA can bind to
ISRE directly and specifically.
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RTA has sequence similarity to IRF family proteins. Since
IRFs have the ability to bind to ISRE, whether RTA has
similarity to IRF family proteins was examined using the
Clustal W program (25, 63). RTA and all human IRF protein
sequences were aligned, and a region with some degree of
similarity was identified (Fig. 4A). The similar regions are
located within the DNA-binding domain (amino acids 1 to 272)
of RTA as well as in the DNA-binding domains of IRFs. The
similarity between RTA and IRF family proteins suggests that
RTA and IRFs may target ISRE by a similar mechanism. The
conserved amino acids in the region with similarity could be
involved in the DNA binding.
FIG. 1. RTA activates the K14-ORF74 promoter though an ISRE-like element. A. Schematic representation of K14-ORF74 promoter region
and reporter constructs. RNA start sites for K14-ORF74 and for LANA are shown and are based on the report of Jeong et al. (26). The K14 ISRE
and its sequence, its mutations, the reporter constructs, and BC-1 genomic coordinates are shown. The mutated nucleotides are underlined. A
previously identified K14 RRE and a putative RRE are also shown. B. K14-ORF74 promoter reporter constructs are inducible in HHV-8-positive
cells. DG 75 is HHV-8 negative, while BC3 is an HHV-8-positive cell line. The reporter constructs were transfected into cells by electroporation.
The fold activation after TPA treatment (24 to 36 h posttreatments) is shown. C. RTA activates K14-ORF74 reporter constructs. 293T cells were
transfected with reporter construct, K14A-luc, or K14B-luc, along with CMV–-Gal and various amounts of RTA expression plasmids (10, 25, and
50 ng). The reporter activity is expressed relative to the vector control. D. RTA activates K14 ISRE. K14 ISRE-luc or mK14ISRE-luc was
transfected with the RTA expression plasmid (0.1 and 0.3 g). The reporter activity is expressed relative to vector control. In these assays,
luciferase activity was normalized by -galactosidase activity. Standard deviations are shown.
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The similarity between IRF and RTA was not particularly
high (Fig. 4A). In order to determine the relevance of the
comparison in Fig. 4A, mutations were made in all of the
completely conserved residues of RTA individually (Fig. 4B),
and their effects on the activation of the K14-ORF74 promoter
reporter constructs were examined upon transfection into
293T cells (Fig. 4C and D). RTA K152E had almost com-
pletely lost its ability to activate the K14-ORF74 promoter and
the K14ISRE promoter reporter constructs (Fig. 4C and D).
The expression levels of these mutant proteins were similar to
the wild-type RTA in 293T cells, except for the RTA-A158P
mutant (Fig. 4E). The RTA-A158P mutant always expressed
lower levels of proteins in our systems, even when threefold
more DNA was used for transfection (data not shown). Thus,
the mutation in A158 may influence the protein expression of
RTA, but it may not affect the transactivation potential of
RTA. Also, these mutants are all localized in the nucleus in a
similar pattern to wild-type RTA (data not shown). These
results suggest that the comparison in Fig. 4A may be relevant.
A mutation in RTA reduced its DNA-binding affinity. Be-
cause RTA K152E and wild-type RTA were both localized in
the nuclei of transfected cells (data not shown), it is possible
that the K152E mutation could have disrupted the DNA-bind-
ing activity of RTA. The RTA-K152E protein was partially
purified from bacteria via a similar procedure as for the wild-
type RTA. The input levels of RTA and RTA K152E proteins
were adjusted to similar levels (Fig. 5C and D), and their
ability to bind to DNA was then tested by EMSA (Fig. 5A and
B). Binding to ISREs by RTA was reproducibly reduced (Fig.
5A). In addition, RTA K152E could only marginally bind to
two well-studied RREs, PAN and ORF57 RREs (Fig. 5B).
Thus, the mutation at K152 may have affected RTA DNA-
binding activity in general.
RTA K152E failed to activate RTA-responsive genes. Since
RTA K152E has a reduced ability to bind to DNA, we tested
its ability to activate RTA-responsive promoter constructs.
RTA K152E was unable to activate several RTA-responsive
promoters (Fig. 6A). The results suggested that RTA K152E
might be unable to activate the lytic replication of HHV-8.
HHV-8-positive BCBL-1 cells were transfected with RTA or
RTA K152E to determine their abilities to induce HHV-8 lytic
gene expression. Due to the low transfection efficiency of
BCBL-1 cells, we used CD4 selection procedures to enrich the
transfected cells (see Materials and Methods for details). RTA
K152E could not induce the expression of several lytic genes,
such as K8, vIRF1, K8.1, and vIL6, all of which were inducible
FIG. 2. The activation domain of RTA is required for activation of the K14-ORF74 promoter. A. Schematic diagram of RTA domains and
mutants. The number of amino acid residues is shown. The basic region of the RTA and leucine zipper regions, activation domain, DNA-binding
domain, and nuclear localization signal (NLS) are shown. B. The activation domain of RTA is required for activation of the K14-ORF74 promoter.
293T cells were transfected with reporter construct, K14A-luc, along with CMV–-Gal and equal amounts (50 ng) of RTA or various mutant
expression plasmids. The relative reporter activity is shown. C. The activation domain of RTA is required for activation of the K14 ISRE. 293T
cells were transfected with reporter construct, K14ISRE-luc along with CMV–-Gal, and equal amounts (0.3 g) of RTA or various mutant
expression plasmids. The reporter activity is expressed relative to the vector control. Luciferase activity was normalized by -galactosidase activity.
Standard deviations are shown. D. Expression status of RTA and its deletion mutants. Western blotting with Flag monoclonal antibody was
performed. The cell lysates from transfected cells are indicated. The identity of proteins is as shown. ns, nonspecific.
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by wild-type RTA (Fig. 6B). The wild-type RTA was appar-
ently expressed at higher levels than the K152E mutant in
BCBL-1 cells (Fig. 6B), which could be due to the autoregu-
lation of RTA expression (15, 49). However, the expression
levels of RTA K152E were comparable to the level of RTA
induced by TPA. Thus, RTA K152E is ineffective in the induc-
tion of HHV-8 lytic gene expression at a level similar to that
induced by TPA (Fig. 6B).
RTA activated several ISG promoter reporter constructs.
Since RTA can bind to ISRE, which is present in all ISGs (50,
55), it is possible that RTA activates ISGs. To test this possi-
bility, two different ISG promoter reporter constructs (ISG-54-
luc and IFI6-16-luc) that contain ISREs and are responsive to
IFN were studied (20). RTA activated both ISG-54 and
IFI6-16 promoter reporter constructs, while the RTA-K152E
mutant could not (Fig. 7A). In addition, the expression levels
of RTA and its mutants were similar in these experiments (Fig.
7B). Thus, RTA was able to activate different ISG promoter
reporter constructs. Since these promoter reporter constructs
contain ISREs, RTA may at least partially activate ISG pro-
moters via ISRE.
RTA selectively induced endogenous ISGs. The binding to
ISRE and activation of the ISG promoter reporter constructs
by RTA suggested that it might also induce the expression of
endogenous ISGs. Because HHV-8 infects endothelial cells
efficiently and the cellular ISGs are induced upon HHV-8 lytic
replication (46), HUVECs were chosen to test the hypothesis.
Five ISGs (ISG-15, and -54, IRF-7, myxovirus resistance pro-
tein 1 [MxA], and STAF-50) were examined. Due to the low
transfection efficiency of HUVECs, the recombinant adenovi-
ruses containing RTA (AdRTA) or GFP (AdGFP) were used
to infect HUVECs and the effects of RTA in these cells were
examined. RTA expression was confirmed by Western blot
analysis (Fig. 7E), and the expression of GFP was confirmed by
the presence of green fluorescent cells under a fluorescence
microscope (data not shown). Endogenous ISG-54 and
STAF-50 RNA expression was increased in RTA-expressing
cells as determined by RT-PCR and RPA (Fig. 7C and D). The
expression of the MxA protein also increased, as determined
by Western blotting (Fig. 7E). However, expression of neither
IRF-7 nor ISG-15 was found to increase significantly in the
presence of RTA (data not shown). Therefore, RTA selec-
tively induces endogenous ISGs. It is of note that wild-type
adenovirus infection induces ISG-15 (43a); the results here
suggested that the induction of these ISGs was not due to the
contamination of wild-type RTA.
FIG. 3. RTA binds to ISRE. A. The purified RTA protein binds to K14 ISRE. The probe was labeled with [-32P]dATP. K14 ISRE, mK14
ISRE, ISG15 ISRE, Tap-2 ISRE, and mTap2-ISRE were used as cold competitors. Cold competitors were added at a 50-fold molar excess over
hot probe. Various amounts of Ni2-NTA agarose beads (1.5, 5, and 15 l) were used to remove the histidine-tagged RTA proteins in an EMSA.
Fifteen microliters of GST beads was used as a control. Rabbit polyclonal anti-RTA or K15 serum was also used. ns, nonspecific. B. RTA binds
to known ISREs. The probe was ISRE-1 from the vIL-6 promoter. The cold competitors, Ni2-NTA agarose beads, GST beads, and antisera used
are shown. Specific protein-DNA complexes are shown.
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DISCUSSION
The structure and functions of RTA have been extensively
studied (16, 68). However, the exact mechanism involved in
RTA functions remains incompletely understood. RTA ap-
pears to activate transcription through two distinct mecha-
nisms, either by direct binding to DNA or via association with
other DNA-binding transcription factors. RREs appear to be
heterogeneous and ill defined (14, 17, 30, 47, 49, 57, 59).
FIG. 4. Mutations in the DNA-binding domain of RTA affect activation of the K14-ORF74 promoter. A. RTA has certain similarities to IRF
proteins. The Clustal W program was used for the alignment of RTA with all human IRF members. Gaps were introduced to allow best alignment.
The identity and coordinates of mutated amino acids in RTA are shown at the bottom with arrows. B. Schematic diagram of RTA mutant
constructs. The coordinates and identities of the amino acids are shown. The positions of amino acids are not on scale. C. Mutations in the
DNA-binding domain of RTA reduce activation of the K14-ORF74 promoter. 293T cells were transfected with reporter construct, K14A-luc, along
with CMV–-Gal and equal amounts (50 ng) of RTA or various mutant expression plasmids. The reporter activity is expressed relative to the vector
control. Luciferase activity was normalized by -galactosidase activity. Standard deviations are shown. D. Mutations in the DNA-binding domain
of RTA reduce activation of K14-ISRE. 293T cells were transfected with reporter construct, K14ISRE-luc, along with CMV–-Gal and equal
amounts (0.3 g) of RTA or various mutant expression plasmids. The reporter activity is expressed relative to the vector control. Standard
deviations are shown. E. Expression levels of RTA mutants. Western blotting with RTA as well as tubulin antibodies was performed. The cell
lysates from transfected cells shown in panels C or D are indicated. The identities of proteins are shown.
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In this study, we have shown that ISRE could serve as an
RRE and that RTA may regulate the K14-ORF74 genes via an
ISRE-like sequence, K14 ISRE. However, K14 ISRE may not
be the sole element in the promoter responsible for RTA
activation: a functional RRE was identified and a putative
RRE has been proposed in the K14-ORF74 promoter region
(Fig. 1A) (26, 30). Indeed, the ISRE-deficient K14-ORF74
promoter reporter construct (K14B-luc) (Fig. 1A), which con-
tains the putative RRE, could also be activated by RTA and
TPA stimulation but at a low efficiency (Fig. 1B and C). Thus,
K14 ISRE, K14 RRE, and an additional RRE(s) may be re-
sponsible for the optimal activation of K14-ORF74 genes by
RTA. Nevertheless, our results demonstrated that K14 ISRE
may play a role in the activation.
Other than K14 ISRE, at least seven other ISRE-like se-
quences can be identified in the HHV-8 (BC-1 strain) genome.
ORF-K2 (vIL-6) is an IFN-inducible viral gene which can also
be activated by RTA, and the vIL-6 promoter contains two
ISREs and one RRE (9, 14). The presence of ISREs suggests
that RTA may activate the vIL-6 promoter via one or both
FIG. 5. RTA K152 E failed to efficiently bind to ISREs or RREs. A. RTA K152 E binds to ISRE with reduced affinities. Equal amounts of
partially purified recombinant RTA and RTA K152E proteins from bacteria were used for EMSA with various probes. The probes were ISRE from
the ISG-15 gene, vIL6 ISRE1, and K14 ISRE. B. RTA K152 E binds to RREs with reduced affinities. Two known RREs, PAN and ORF57 RREs,
were used for EMSA. Cold competitors and protein used are indicated on top. The RTA-DNA complexes are shown. C. Coomassie blue staining
of the partially purified E. coli-derived RTA and its mutant RTA K152E proteins. Molecular mass (MW) markers and their sizes in kilodaltons
are also shown. D. Western blot analysis of E. coli-derived RTA and its mutant RTA K152E. His tag and RTA antibodies were used for detection
of partially purified proteins as shown in panel C. Some MW markers were also reactive to His tag antibody as shown.
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vIL-6 ISREs in the absence of the identified RRE. As ex-
pected, RTA could efficiently activate vIL-6 promoter reporter
constructs that lacked the identified RRE (data not shown),
and RTA could bind to at least one of the two vIL6 ISREs
(Fig. 3 and 5). These results thus suggest that the binding of
RTA to ISRE may play a regulatory role in the control of
different viral gene expressions.
A previous report suggested that RTA binds to multiple,
phased A/T triplets in RRE to bring about potent transcrip-
tional activation (Table 1). ISREs are loosely conserved, but
one conserved feature is the two consecutive A triplets, i.e.,
AAANNNAAA, in the consensus sequence (Table 1) (12, 55,
62). Thus, our data in this report are in agreement with the
published results (30). It is likely that ISRE is a variant of
consensus RREs except for the spacer regions between the two
A triplets.
Lysine 152 of RTA, which is conserved among RTA and
IRFs, plays a critical role in RTA functions. In addition, the
same lysine in IRF-1 (K78) was implicated in IRF-1–DNA
contact (18). Thus, the lysine residue may also be a critical one
in the biological functions of the IRF family. To examine the
functional role of the lysine in the IRF family, we have mutated
the lysine residue (K92) in IRF-7 because IRF-7 and RTA
have similar lengths in the similarity region (Fig. 4A). We then
examined the properties of the particular mutant (IRF7-K92E)
on DNA binding and on activation of the IFN- promoter,
because IRF-7 is a critical determinant for the induction of
IFN-/ genes in response to viral infection (3, 33, 37, 67, 75).
IRF7-K92E failed to bind to DNA efficiently (Fig. 8A), and the
IRF7-K92E failed to activate the IFN promoter (Fig. 8B);
however, the infection of transfected cells with Sendai virus led
to activation of IRF7 K92E, as judged by the nuclear translo-
cation after viral infection (data not shown). These results
strongly suggested that the comparison between RTA and
IRFs in Fig. 4A is relevant.
IRFs are capable of binding to DNA by a helix-turn-helix
motif, and the corresponding lysine K78 in IRF-1 is located in
the DNA recognition helix of IRF-1 (18). The corresponding
region of RTA is predicted to form a helix (data not shown).
Our study has shown that the conserved lysine plays a critical
role in both RTA and IRF-7. These data collectively suggest
that RTA might use a similar helix-turn-helix motif to bind to
DNA as IRF, and lysine 152 of RTA may be an important
residue involved in the RTA-DNA interaction. Due to the fact
that RTA K152E fails to bind to DNA efficiently and to induce
lytic gene expression, it suggests that the DNA-binding activity
of RTA is a prerequisite for its transactivation function and
disruption of viral latency.
ISRE is present in the promoters of all ISGs (50, 55, 62).
Our data demonstrated that two ISG promoters could be ac-
tivated by RTA, and RTA could induce some endogenous
ISGs, such as ISG-54, MxA, and STAF-50 (Fig. 7). The selec-
tive induction of ISGs by RTA was not unexpected, as not all
IRFs can induce ISGs (44, 50, 55, 62) and IFN induces differ-
ent sets of ISGs in various cell lines (53). The selectivity may
also be due to differences in the affinities of RTA to various
ISREs, or cell type-specific factors. The induction of ISGs
upon HHV-8 lytic replication has been reported (46), and
STAF-50 RNA was shown to be highly expressed in KS spec-
imens (48). Since many KS cells undergo spontaneous lytic
replication (16, 39, 68), the induction of STAF-50 may be
relevant to lytic replication and might be mediated in part by
FIG. 6. RTA K152 E failed to induce lytic gene expression efficiently. A. RTA K152E failed to activate RTA-responsive promoter reporter
constructs. The promoter constructs were transfected into 293T cells along with the same amounts (0.3 g) of RTA or RTA K152E expression
plasmid. Luciferase activity was normalized by -galactosidase activity. The relative reporter activities are shown with standard deviations. B. RTA
K152E failed to induce lytic gene expression. RTA or RTA K152E plasmids were transfected with CD4 expression plasmid into BCBL-1 cells, and
the transfected cells were selected by using CD4 magnetic beads. Lysates from transfected and selected cells were used for Western blot analysis.
The identities of proteins are shown.
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FIG. 7. RTA selectively induces the expression of IFN-stimulated genes. A. RTA activates IFN-inducible promoter reporter constructs.
ISG54-luc or IFI6-16-luc promoter constructs were transfected into 293T cells along with various amounts of RTA expression plasmids (0.1 or 0.3
g) or with RTA K152E expression plasmid (0.3 g). Luciferase activity was normalized by -galactosidase activity. The relative reporter activities
are shown with standard deviations. B. Expression levels of RTA mutants. Western blot assays with RTA as well as tubulin antibodies were
performed. The cell lysates from transfected cells are indicated. The identities of proteins are shown. C. RTA induces ISG-54 in HUVECs. RNAs
from uninfected HUVECs or the cells infected with recombinant adenovirus with RTA or GFP, respectively, were used for RT-PCR analyses.
IFN- (100 IU/ml)-treated 293 cells were used as a positive control. D. RTA induces STAF-50 in HUVECs. STAF-50 and GAPDH probes were
labeled with [-32P]UTP and used for RPA. Specific protections of STAF-50 and GAPDH mRNAs and undigested probes are indicated. Relative
STAF-50 RNA levels (STAF-50/GAPDH) were increased 5.3 	 0.9-fold. The data were obtained by normalizing STAF-50 to GAPDH levels from
three independent experiments with the use of a Gene Genius Bioimaging system. E. RTA induces the expression of MxA protein. Lysates from
uninfected, AdRTA-infected, AdGFP-infected, or IFN- (100 IU/ml)-treated HUVECs were used for Western blot analysis. The same membrane
was stripped and reprobed with other antibodies. The identities of proteins are shown.
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RTA. It is of note that the induction of ISGs appears to be a
common phenomenon upon herpesvirus infection (5, 41, 42,
46, 56, 79). Although the exact functions of these induced ISGs
are currently unknown, it is likely that these genes may play a
role in viral replication and pathogenic processes.
Because ISG induction is a major outcome upon IFN treat-
ment, one possibility is that the activation of ISGs by RTA is
indirect via the induction of IFNs. However, it is unlikely for
several reasons. The selective induction of ISGs suggests that
IFN may not be involved, since IFN induces IRF-7 and ISG15
in HUVECs (data not shown). The culture medium from
RTA-transfected cells could not induce ISGs when transferred
to fresh cells. No significant induction of IFN by RTA was
observed by RT-PCR analyses (data not shown). Moreover,
the induction of ISGs during HHV-8 lytic replication was
shown to be independent of IFNs (10). Finally, IFN was not
involved in the induction of ISGs upon infections by other
herpesviruses (5, 6, 42, 56, 79). Thus, it is likely that the ob-
served activation of ISGs is a direct effect of RTA rather than
an indirect effect via IFN.
HHV-8 has been known to contain several different cellular
homologues, including four vIRFs that appear to play an im-
portant role in HHV-8 pathogenesis (39, 40). These vIRFs
have some homology to the IRF family proteins, but none of
these vIRFs has been shown to bind to ISRE. Our data suggest
that RTA has a region with sequence similarity to IRFs and
binds to ISRE. In addition, the activation of ISG promoters,
induction of endogenous ISGs, and similarity between RREs
and ISREs (Table 1) provide additional evidence that RTA
and IRFs have similar functional properties. Because RTA is
loosely conserved in the gammaherpesvirus family, RTAs of
other gammaherpesviruses might also have similar properties.
Indeed, EBV RTA was also able to induce at least two ISGs
(data not shown). Thus, our findings may not only shed new
light on the mechanisms of HHV-8 RTA but also other RTAs
in the regulation of both viral and cellular genes.
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